Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRTCI: SIRT + XELOX + Bevacizumab + Atezolizumab in mCRC
NCT04659382Phase 2Unknown
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in metastatic colorectal cancer (mCRC), sponsored by Fédération Francophone de Cancérologie Digestive. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04659382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659382.